Compounding HRT Solutions for Women with PMS or PMDD

According to ACOG and NIH MedlinePlus, in PMS and PMDD mood swings may present as rapid, cyclical shifts in emotional state that emerge during the luteal phase and are thought to reflect heightened sensitivity to normal hormonal fluctuations rather than absolute hormone excess or deficiency. These shifts may include sudden irritability, episodes of anger disproportionate to circumstance, tearfulness, transient anxiety, and a sense of low mood or hopelessness. According to ACOG, in PMDD these mood fluctuations may cause clear functional impairment in work, relationships, or daily activities. Patients experiencing severe or persistent mood disturbance, thoughts of self-harm, or significant functional impairment should seek evaluation from a qualified clinician promptly, as sudden worsening of mood symptoms may indicate a condition requiring urgent assessment.

According to ACOG and NIH MedlinePlus, in PMS and PMDD irritability may present as heightened reactivity to everyday stressors, a reduced threshold for frustration, and interpersonal friction that worsens in the luteal phase before menses and typically remits within days of the onset of menstrual bleeding. According to ACOG, irritability is among the most commonly reported and disruptive symptoms in PMDD, and may be accompanied by anger, conflict in close relationships, and difficulty regulating emotional responses. Patients whose irritability is severe, causes significant distress, or is accompanied by aggressive behavior should seek evaluation from a qualified clinician, as these presentations may indicate a more serious mood condition requiring clinical management.

According to ACOG and NIH MedlinePlus, in PMS and PMDD depressed mood may present as persistent low mood, tearfulness, diminished interest in usual activities, feelings of worthlessness or hopelessness, and heightened sensitivity to rejection during the luteal phase of the menstrual cycle. According to ACOG, these symptoms are more severe and functionally impairing in PMDD and typically remit within days after the onset of menses, following a clear cyclical pattern that distinguishes them from a persistent depressive disorder. Patients experiencing severe depressed mood, thoughts of hopelessness, or any thoughts of self-harm should seek evaluation from a qualified clinician without delay, as such presentations may indicate a serious mood disorder requiring urgent clinical attention.

According to ACOG and NIH MedlinePlus, in PMS and PMDD anxiety may present as a persistent sense of dread, excessive worry, racing thoughts, and difficulty concentrating that worsens during the luteal phase before menses and improves after bleeding begins. Physical manifestations may include heart palpitations, sweating, trembling, and a subjective sense of being on edge. According to ACOG, anxiety in PMDD may escalate to episodes of intense fear or irritability that interfere with sleep, work, and relationships. Patients experiencing severe anxiety, chest pain, or sudden onset of intense fear should seek prompt evaluation from a qualified clinician, as these symptoms may indicate a condition requiring urgent medical assessment beyond routine premenstrual symptom management.

According to the FDA-approved prescribing information for Prometrium, Prometrium (progesterone, USP) is a progestogen indicated for the prevention of endometrial hyperplasia in non-hysterectomized postmenopausal women receiving conjugated estrogens tablets, and for the treatment of secondary amenorrhea. The labeling describes that Prometrium is a micronized oral progesterone that exerts progestational effects on the endometrium. Per the labeling, adverse reactions may include headache, dizziness, breast tenderness, and somnolence, and use may be associated with cardiovascular risks, probable dementia in women 65 years of age or older when used in combination with estrogen, and other serious risks described in the FDA boxed warning. According to the FDA-approved prescribing information for Prometrium, the labeling carries a boxed warning noting that progestins combined with estrogens should not be used for the prevention of cardiovascular disease or dementia and that increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis have been reported in postmenopausal women. Any compounded preparation involving progesterone is not reviewed by FDA for safety or effectiveness before dispensing. Commercially available Prometrium products are separately regulated, and clinical decisions belong with the prescribing clinician.

According to the FDA-approved prescribing information for Vivelle-Dot, Vivelle-Dot (estradiol transdermal system) is an estrogen indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause, the treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with menopause, the prevention of postmenopausal osteoporosis, and the treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian insufficiency. The labeling describes that the transdermal system delivers 17β-estradiol continuously through the skin, producing steady systemic estrogen levels while bypassing first-pass hepatic metabolism. Per the labeling, serious risks may include endometrial cancer in women with a uterus not receiving a progestogen, cardiovascular disorders, breast cancer, and probable dementia; the labeling carries a boxed warning noting that estrogens should not be used for the prevention of cardiovascular disease or dementia and that increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis have been reported. Any compounded preparation involving transdermal estradiol is not reviewed by FDA for safety or effectiveness before dispensing. Commercially available Vivelle-Dot products are separately regulated, and clinical decisions belong with the prescribing clinician.